Published in Dig Dis Sci on July 26, 2008
Acute liver injury induced by weight-loss herbal supplements. World J Hepatol (2010) 1.57
Hepatoxicity associated with weight-loss supplements: a case for better post-marketing surveillance. World J Gastroenterol (2009) 1.15
Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol (2010) 1.14
A finished dietary supplement stimulates lipolysis and metabolic rate in young men and women. Nutr Metab Insights (2011) 1.13
Hydroxycut(®) (herbal weight loss supplement) induced hepatotoxicity: a case report and review of literature. Hawaii Med J (2010) 1.08
Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps. Front Pharmacol (2015) 1.04
Liver Injury from Herbal, Dietary, and Weight Loss Supplements: a Review. J Clin Transl Hepatol (2015) 1.03
In vitro and in vivo toxicity of garcinia or hydroxycitric Acid: a review. Evid Based Complement Alternat Med (2012) 0.98
Garcinia Cambogia attenuates diet-induced adiposity but exacerbates hepatic collagen accumulation and inflammation. World J Gastroenterol (2013) 0.88
Sensitivity to hepatotoxicity due to epigallocatechin gallate is affected by genetic background in diversity outbred mice. Food Chem Toxicol (2014) 0.88
Hydroxycut-induced Liver Toxicity. Ann Med Health Sci Res (2014) 0.86
Adverse effects of plant food supplements and botanical preparations: a systematic review with critical evaluation of causality. Br J Clin Pharmacol (2015) 0.84
No evidence demonstrating hepatotoxicity associated with hydroxycitric acid. World J Gastroenterol (2009) 0.84
Herbal Hepatotoxicity: Clinical Characteristics and Listing Compilation. Int J Mol Sci (2016) 0.82
Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics. Int J Mol Sci (2016) 0.82
Scientific and Regulatory Perspectives in Herbal and Dietary Supplement Associated Hepatotoxicity in the United States. Int J Mol Sci (2016) 0.81
What's new about inflammatory bowel diseases in Ischemic colitis induced by the newly reformulated multicomponent weight-loss supplement Hydroxycut(®). World J Gastrointest Endosc (2013) 0.77
Acute liver injury associated with a newer formulation of the herbal weight loss supplement Hydroxycut. BMJ Case Rep (2015) 0.76
Epigallocatechin gallate does not accelerate the early phase of liver regeneration after partial hepatectomy in rats. Dig Dis Sci (2013) 0.76
Dangerous dietary supplements: Garcinia cambogia-associated hepatic failure requiring transplantation. World J Gastroenterol (2016) 0.75
Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl (2006) 2.13
Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med (2006) 1.95
Two patients with acute liver injury associated with use of the herbal weight-loss supplement hydroxycut. Ann Intern Med (2005) 1.43
Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. Eur J Gastroenterol Hepatol (2005) 1.31
Toxicity of green tea extracts and their constituents in rat hepatocytes in primary culture. Food Chem Toxicol (2005) 1.14
Fatal liver failure following food supplements during chronic treatment with montelukast. Dig Liver Dis (2006) 1.11
[Liver toxicity of Camellia sinensis dried etanolic extract]. Med Clin (Barc) (2003) 0.93
[Acute hepatitis associated with Camellia thea and Orthosiphon stamineus ingestion]. Gastroenterol Hepatol (2004) 0.91
[Acute hepatitis due to Exolise, a Camellia sinensis-derived drug]. Gastroenterol Clin Biol (2003) 0.85
[Hepatotoxicity due to Camelia sinensis]. Med Clin (Barc) (2004) 0.83
[Acute cytolysis induced by Chinese tea]. Gastroenterol Clin Biol (2002) 0.81
Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int (2011) 3.36
Donor and recipient outcomes in right lobe adult living donor liver transplantation. Liver Transpl (2002) 2.98
Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol (2010) 2.63
Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology (2006) 2.62
Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2008) 2.30
Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm (2008) 2.16
Ammonia levels and the severity of hepatic encephalopathy. Am J Med (2003) 2.14
Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology (2004) 1.80
Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg (2005) 1.73
Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology (2005) 1.66
Endoscopic treatment of postorthotopic liver transplantation anastomotic biliary strictures with maximal stent therapy (with video). Gastrointest Endosc (2010) 1.65
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology (2010) 1.56
Treating hepatitis C in the prison population is cost-saving. Hepatology (2008) 1.50
Health-related quality of life predicts mortality in patients with advanced chronic liver disease. Clin Gastroenterol Hepatol (2009) 1.42
Kidney transplantation threshold in patients with hepatitis C: a decision analysis model. Transplantation (2015) 1.38
Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol (2008) 1.37
Treatment of hepatitis C. Am J Med (2005) 1.35
Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology (2007) 1.31
Long-term patient outcome and quality of life after liver transplantation: analysis of 20-year survivors. Ann Surg (2010) 1.28
Severe psychiatric problems in right hepatic lobe donors for living donor liver transplantation. Transplantation (2007) 1.26
Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg (2002) 1.22
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology (2013) 1.21
Postresection hepatic failure: successful treatment with liver transplantation. Liver Transpl (2007) 1.20
Viral hepatitis in incarcerated adults: a medical and public health concern. Am J Gastroenterol (2009) 1.17
Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period. Ann Surg (2003) 1.15
Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review. Liver Int (2010) 1.14
Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. Liver Transpl (2004) 1.12
Effects of a nurse-managed program on hepatitis A and B vaccine completion among homeless adults. Nurs Res (2008) 1.11
The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center. Ann Surg (2013) 1.08
Immunization needs of chronic liver disease patients seen in primary care versus specialist settings. Dig Dis Sci (2005) 1.03
Pregnancy and cirrhosis. Liver Transpl (2008) 1.01
Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors, incidence and management. Liver Int (2010) 1.00
A model to predict the development of mental status changes of unclear cause after liver transplantation. Liver Transpl (2003) 1.00
Pregnancy and liver transplantation. Liver Int (2008) 1.00
Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int (2007) 0.98
Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2011) 0.98
Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology (2004) 0.96
Health-related quality of life after liver transplantation for adult recipients. Liver Transpl (2009) 0.96
Economic burden associated with patients diagnosed with hepatitis C. Clin Ther (2011) 0.95
Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg (2011) 0.95
Hepatitis B surface antigenemia in chronic hemodialysis patients: effect of hepatitis B immunization. Am J Gastroenterol (2002) 0.93
The effects of hepatitis C recurrence on health-related quality of life in liver transplant recipients. Liver Int (2009) 0.93
Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis. Dig Dis Sci (2009) 0.93
Management of Hepatitis C Antiviral Therapy Adverse Effects. Curr Hepat Rep (2010) 0.92
New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg (2002) 0.91
Fulminant liver failure due to usnic acid for weight loss. Am J Gastroenterol (2004) 0.91
Endoscopic treatment with multiple stents for post-liver-transplantation nonanastomotic biliary strictures. Gastrointest Endosc (2009) 0.91
Regional variation in the cost effectiveness of childhood hepatitis A immunization. Pediatr Infect Dis J (2003) 0.89
Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) for Treatment of Gastric Varices: Review and Meta-Analysis. Dig Dis Sci (2014) 0.89
Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma. J Am Coll Surg (2011) 0.89
Presence and predictors of hepatitis C virus RNA in the semen of homeless men. Biol Res Nurs (2002) 0.87
Liver transplantation in the era of model for end-stage liver disease. Liver Int (2004) 0.85
Complications of cirrhosis. Dis Mon (2008) 0.85
Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver Int (2014) 0.85
The cost effectiveness of hepatitis immunization for US college students. J Am Coll Health (2003) 0.83
Primary prevention of cirrhosis. Public health strategies that can make a difference. Postgrad Med (2004) 0.83
Hyponatremia: clinical associations, prognosis, and treatment in cirrhosis. Exp Clin Transplant (2013) 0.82
Management of recurrent hepatocellular carcinoma in liver transplant recipients: a systematic review. Exp Clin Transplant (2012) 0.82
Hepatitis C and lymphoproliferative disorders: from mixed cryoglobulinemia to non-Hodgkin's lymphoma. Clin Gastroenterol Hepatol (2009) 0.82
Patients with nodular regenerative hyperplasia should be considered for hepatocellular carcinoma screening. Hepatol Res (2013) 0.81
Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues. Liver Transpl (2013) 0.81
A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection. Hepatol Int (2010) 0.81
Deciding liver transplant candidacy: tools of the trade. Liver Int (2008) 0.80
Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg (2006) 0.80
Capsule endoscopy is not as accurate as esophagogastroduodenoscopy in screening cirrhotic patients for varices. Clin Gastroenterol Hepatol (2011) 0.80
Recurrence of non-viral liver disease after orthotopic liver transplantation. Liver Int (2011) 0.80
Timing of Hepatitis C Antiviral Therapy in Liver Transplant Recipients With Direct-acting Agents. Exp Clin Transplant (2016) 0.80
An economic assessment of pre-vaccination screening for hepatitis A and B. Public Health Rep (2003) 0.80
The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy. Clin Transplant (2014) 0.78
Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study. Hepatology (2014) 0.78
Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response. Curr Hepat Rep (2010) 0.78
A proposed, evidence-based approach to the treatment of chronic Hepatitis B. J Clin Gastroenterol (2011) 0.77
Cirrhosis regression in patients with viral hepatitis B and C: a systematic review. J Clin Gastroenterol (2014) 0.77
Impact of nutrition and obesity on chronic liver disease. Clin Liver Dis (2013) 0.77
Hepatitis C and work impairment: a review of current literature. J Clin Gastroenterol (2014) 0.77
Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care. Medicine (Baltimore) (2016) 0.77
Recurrent non-alcoholic steatohepatitis in a living related liver transplant recipient. J Hepatol (2005) 0.77
Inpatient economic and mortality assessment for liver transplantation: a nationwide study of the United States data from 2005 to 2009. Transplantation (2014) 0.77
Timing of Hepatitis C Antiviral Therapy in Liver Transplant Recipients With Direct-acting Agents. Exp Clin Transplant (2016) 0.76
Cirrhosis with refractory ascites: serial large volume paracentesis, TIPS, or transplantation? Clin Gastroenterol Hepatol (2011) 0.76
Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity. Clin Transplant (2013) 0.75
Can daily coffee consumption reduce liver disease-related mortality? Clin Gastroenterol Hepatol (2013) 0.75
A parathyroid hormone-related protein-secreting metastatic epithelioid leiomyosarcoma. A case report and review of the literature. Arch Pathol Lab Med (2003) 0.75
Efficacy of CT angiography for preoperative vascular mapping in adult to adult living related liver transplant donors. J Med Assoc Thai (2011) 0.75
Treating Medicaid patients with hepatitis C: clinical and economic impact. Am J Manag Care (2017) 0.75
Liver transplant: a primer. Exp Clin Transplant (2010) 0.75
Age-related Morbidity and Mortality After Transjugular Intrahepatic Portosystemic Shunts. J Clin Gastroenterol (2017) 0.75
Treatment of Patients With Hepatitis C Virus infection (Genotype 4) With Ledipasvir-Sofosbuvir in the Liver Transplant Setting. Transplantation (2017) 0.75
Preoperative imaging in adult-to-adult living related liver transplant donors: what surgeons want to know. J Comput Assist Tomogr (2004) 0.75
Viral breakthrough is associated with resistance using direct acting agents in patients treated for chronic hepatitis C infection. J Clin Gastroenterol (2014) 0.75